Cure Medical is pleased to announce a strategic business collaboration with InMode UK, marking a significant milestone in the continued growth of both organisations within the UK and Irish medical aesthetics market.
This collaboration brings together two highly complementary portfolios and commercial strengths, uniting InMode UK’s established range of innovative, energy-based aesthetic devices with Cure Medical’s advanced topical and device-led skin solutions. The result is a broader, more comprehensive offering designed to meet the evolving needs of surgeons, doctors, dentists, medical practitioners, and aesthetic clinics across the UK and Ireland.
Demand for high-quality, clinically proven, energy-based aesthetic technologies continues to accelerate as practitioners seek reliable, versatile solutions delivered through a trusted commercial partner. As the market matures, clinics increasingly value streamlined partnerships that combine advanced technology, robust clinical support, and strong commercial infrastructure.
With over 20 years of experience in the UK and Irish aesthetics industry, Cure Medical brings deep commercial insight and a proven track record in successfully launching and scaling leading aesthetic brands. This includes playing a key role in the successful market penetration of internationally recognised platforms such as Alma Lasers across the UK and Ireland.
Entering 2026, this collaboration positions both companies to respond decisively to increasing demand for integrated, future-focused aesthetic solutions.
Through this strategic collaboration, Cure Medical and InMode UK will align their marketing and sales activities, operating as a unified commercial team throughout the UK. By combining complementary strengths, the collaboration delivers a more robust commercial structure, supported by experienced leadership and a strong, customer-focused organisation.
This unified approach ensures clinics benefit from a wider portfolio of technologies, enhanced support, and a single point of commercial alignment, without compromising on quality, innovation, or clinical outcomes.
Commenting on the collaboration, Moshe Mizrahy, CEO of InMode, said:
“This collaboration represents an important step in strengthening our position in the UK. By combining InMode UK’s established presence with Cure Medical’s commercial expertise and Adam’s leadership, we are creating strong synergies that will support our customers and partners long term.”
Adam Bashir, Managing Director of InMode Cure Medical, added:
“With InMode UK poised for the next phase of growth, together with the complementary portfolio of Cure Medical advanced skin solutions such as ExoCoBio, TriWorks, and Classys, this collaboration is exceptionally timely. It allows us to achieve critical mass and accelerate our ambition to become the leading company in medical aesthetics across the UK and Ireland.”
With a strengthened leadership structure and an expanded commercial collaboration, Cure Medical and InMode UK enter 2026 in a significantly enhanced position. By combining a globally recognised brand, a broader and more comprehensive portfolio of medical aesthetic skin solutions, and an experienced management team, the collaboration is uniquely positioned to deliver increased value to clinics and practitioners.
Together, Cure Medical and InMode UK look forward to continuing their close partnerships with doctors and clinics throughout 2026 and to playing a leading role in shaping the future of the UK medical aesthetics market.
Best wishes,
Adam Bashir
Managing Director, InMode & Cure Medical
Fill out the form below, or contact us so we can schedule your AgeJet demo free of charge and without any commitment.
